{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-040752","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.510770+00:00","generated_at":"2026-05-30T16:13:04.611035+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Israeli Ministry of Health approves Elite's generic Adderall; first shipment months away","bullets":["Israeli Ministry of Health approved Elite's generic Adderall (mixed amphetamine salts) in 10mg, 20mg, 30mg tablets on Oct 7, 2024.","Elite will supply to exclusive distributor Dexcel Pharma for the Israeli market; Dexcel handles sales/marketing at its expense.","Product jointly owned by Elite and Mikah Pharma; first shipment depends on licensee orders, DEA quotas, and manufacturing.","Under license agreement, Dexcel pays transfer price and shares profits under certain conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-040752","json":"https://secwatch.observer/filing/0001493152-24-040752.json","markdown":"https://secwatch.observer/filing/0001493152-24-040752.md","text":"https://secwatch.observer/filing/0001493152-24-040752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224040752/0001493152-24-040752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224040752/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:13:04.611035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}